Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B

News Daily News

Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B

Michael O'Riordan

June 24, 2024

Evinacumab Helps Severe Hypercholesterolemia Patients Reach LDL Targets

News Daily News

Evinacumab Helps Severe Hypercholesterolemia Patients Reach LDL Targets

Michael O'Riordan

September 14, 2023

More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

News Conference News ESC 2022

INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

Michael O'Riordan

August 28, 2022

Homozygous FH Diagnosis Often Comes Late, With Lackluster Care

News Daily News

Homozygous FH Diagnosis Often Comes Late, With Lackluster Care

Michael O'Riordan

February 10, 2022

Rilonacept Prevents Recurrent Pericarditis: RHAPSODY

News Conference News AHA 2020

Rilonacept Prevents Recurrent Pericarditis: RHAPSODY

November 17, 2020

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

Rising Inflammatory Tides: Increasing CRP Levels After ACS Tied to Greater CVD Risks

News Daily News

Rising Inflammatory Tides: Increasing CRP Levels After ACS Tied to Greater CVD Risks

Michael O'Riordan

March 08, 2019

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

News Features

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Michael O'Riordan

February 01, 2019

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

News Conference News AHA 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

November 05, 2018

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

News Daily News

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Michael O'Riordan

November 01, 2018

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

News Conference News AHA 2017

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Michael O'Riordan

November 13, 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

News Daily News

AstraZeneca Strives to Block Generic Crestor as Observers Call Foul

Michael O'Riordan

July 13, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.